<DOC>
	<DOCNO>NCT00452075</DOCNO>
	<brief_summary>A phase II study Tarceva ( Erlotinib ) predictive marker first-line treatment advance non-small cell lung cancer patient unfit chemotherapy ( NSCLC ) Clinical Phase II Stage IIIB IV non-small cell lung cancer ( NSCLC ) Primary end point : Disease control rate ( = CR+PR SD 8 week /patients ) . Secondary end point : Safety ( Serious Adverse Events , Adverse Events leading premature withdrawal , unexpected TarcevaTM related AEs ) .Correlation EGFR expression rate ( HER1 ) FISH potentially predictive response . An open-label , non randomize , multicenter , clinical trial TarcevaTM single agent The sample size 29 patient 2 stage base Simon´s optimal 2 stage design . Stage 1 accrue 10 patient , less 1 response observe study stop ; 1 response observe accrual continue till 29 patient . A total 29 patient would enter treatment declared sufficient activity deserve attention least 5 patient obtain disease control .</brief_summary>
	<brief_title>Erlotinib First-line Treatment Advanced Non-small Cell Lung Cancer ( NSCLC ) Patients Unfit Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histological cytological document diagnosis inoperable , locally advanced , recurrent metastatic ( Stage IIIB Stage IV ) NSCLC . Chemonaïve patient . Patients investigator 's opinion medically suitable chemotherapy . Measurable disease accord RECIST criterion . ECOG performance status 0 3 . Life expectancy least 12 week . Patients must able take oral medication . Serum calcium within normal range ≥ 4 week since prior surgery radiation therapy For female childbearing potential negative pregnancy test must obtain within 48 hour start therapy must use effective contraception 18 year age old Written ( sign ) Informed Consent participate study Prior systemic antitumor therapy Any unstable systemic disease accord investigator contraindicates use study drug render subject high risk treatment complication ( include active infection , unstable angina , myocardial infarction within previous month , inflammatory bowel disease , hepatic disease serum bilirubin ≥ 2 upper limit normal ( ULN ) AST and/or ALT ≥ 2 x ULN ( ≥ 5 x ULN clearly attributable liver metastasis ) , renal disease acute renal failure serum creatinine ≥ 5 x ULN . Any malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer ) . Nursing mother pregnant woman . Hypersensitivity Tarceva coformulants . Patients brain metastasis spinal cord compression yet definitively treat surgery and/or radiation . Patients brain metastasis spinal cord compression stable condition despite treatment steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>EGFR expression</keyword>
	<keyword>erlotinib</keyword>
</DOC>